

Manuscript Number: FOODCHEM-D-15-03601R1

Title: Hydroxytyrosol targets extracellular matrix remodeling by endothelial cells and inhibits both ex vivo and in vivo angiogenesis

Article Type: Research Article (max 7,500 words)

Keywords: angiogenesis; aortic ring assay; BAEC; CAM assay; hydroxytyrosol; MMP; TIMP; uPA

Corresponding Author: Dr. Miguel Angel Medina,

Corresponding Author's Institution: University of Málaga

First Author: Javier A García-Vilas

Order of Authors: Javier A García-Vilas; Ana R Quesada; Miguel Ángel Medina

Abstract: The health benefits of olive oil are attributed to their bioactive compounds, such as hydroxytyrosol. Previously, we demonstrated that hydroxytyrosol inhibits angiogenesis in vitro. The present study aimed to: i) get further insight into the effects of hydroxytyrosol on extracellular matrix remodeling; and ii) test whether hydroxytyrosol is able to inhibit angiogenesis ex vivo and in vivo. Hydroxytyrosol induced a shift toward inhibition of proteolysis in endothelial cells, with decreased expression of extracellular matrix remodeling-enzyme coding genes and increased levels of some of their inhibitors. Furthermore, this work demonstrated that hydroxytyrosol, at concentrations within the range of its content in virgin olive oil that can be absorbed from moderate and sustained virgin olive oil consumption, is a strong inhibitor of angiogenesis ex vivo and in vivo. These results suggest the need for translational studies to evaluate the potential use of hydroxytyrosol for angio-prevention and angiogenesis inhibition in clinical setting.

This is the preprint version of our manuscript, corresponding to the article that has been published in final form at FOOD CHEMISTRY with DOI: 10.1016/j.foodchem.2016.10.111

1 **Hydroxytyrosol targets extracellular matrix remodeling by endothelial cells and inhibits**  
2 **both *ex vivo* and *in vivo* angiogenesis**

3 Javier A. García-Vilas<sup>a,b</sup>, Ana R. Quesada<sup>a,b</sup> and Miguel Ángel Medina<sup>a,b</sup> \*

4 <sup>a</sup>Universidad de Málaga, Andalucía Tech, Departamento de Biología Molecular y Bioquímica,  
5 Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga)

6 <sup>b</sup>CIBER de Enfermedades Raras (CIBERER), E-29071 Málaga, Spain

7  
8  
9 **\*Corresponding author:** Dr. Miguel Ángel Medina, Departamento de Biología Molecular y  
10 Bioquímica, Facultad de Ciencias, Universidad de Málaga, E-29071, Málaga. Phone: +34-  
11 952137132. Fax. +34-952131674. E-Mail: [medina@uma.es](mailto:medina@uma.es)

12  
13  
14 **Running title:** Antiangiogenic hydroxytyrosol  
15  
16

17 **Abstract**

18 The health benefits of olive oil are attributed to their bioactive compounds, such as  
19 hydroxytyrosol. Previously, we demonstrated that hydroxytyrosol inhibits angiogenesis *in vitro*.  
20 The present study aimed to: i) get further insight into the effects of hydroxytyrosol on  
21 extracellular matrix remodeling; and ii) test whether hydroxytyrosol is able to inhibit  
22 angiogenesis *ex vivo* and *in vivo*. Hydroxytyrosol induced a shift toward inhibition of  
23 proteolysis in endothelial cells, with decreased expression of extracellular matrix remodeling-  
24 enzyme coding genes and increased levels of some of their inhibitors. Furthermore, this work  
25 demonstrated that hydroxytyrosol, at concentrations within the range of its content in virgin  
26 olive oil that can be absorbed from moderate and sustained virgin olive oil consumption, is a  
27 strong inhibitor of angiogenesis *ex vivo* and *in vivo*. These results suggest the need for  
28 translational studies to evaluate the potential use of hydroxytyrosol for angio-prevention and  
29 angiogenesis inhibition in clinical setting.

30

31

32 **Keywords:** angiogenesis; aortic ring assay; bovine aorta endothelial cells (BAEC);  
33 chorioallantoic membrane (CAM) assay; hydroxytyrosol; matrix metalloproteinase (MMP);  
34 tissue inhibitor of metalloproteinase (TIMP); urokinase-type plasminogen activator (uPA)

35

## 36 1. Introduction

37 The phenolic compounds in extra virgin olive oil are bioactive compounds with well-  
38 documented beneficial effects (Fortes, García-Vilas, Quesada & Medina, 2012; Owen et al.,  
39 2000) these compounds are not essential in the sense that nutrients are. In fact, the European  
40 Union has authorized a health claim for polyphenols, based on consumption of olive oil  
41 polyphenols, for the protection of blood lipids from oxidative stress ("Commission Regulation  
42 (EU) 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods,  
43 other than those referring to the reduction of disease risk and to children's development and  
44 health. O.J. 2012, L136/1," 2012). Hydroxytyrosol or 3,4-dihydroxyphenyl ethanol is claimed  
45 to be the most important health-related phenolic compound of virgin olive oil (Lopez de Las  
46 Hazas, Rubio, Kotronoulas, de la Torre, Sola & Motilva, 2015). Along with its cardioprotective  
47 effects (Mnafgui et al., 2015; Samuel, Thirunavukkarasu, Penumathsa, Paul & Maulik, 2008),  
48 beneficial effects of hydroxytyrosol for human health include its antifungal (Zoric et al., 2013),  
49 antidiabetic (Tutino, Orlando, Russo & Notarnicola, 2015; Zheng, et al., 2015), neuroprotective  
50 (De La Cruz, et al., 2015; Gallardo, Madrona, Palma-Valdes, Espartero & Santiago, 2015), anti-  
51 inflammatory (Fuccelli, Fabiani, Sepporta & Rosignoli, 2015; Persia, Mariani, Fogal & Penissi,  
52 2014; Silva et al., 2015) and antitumoral (Granados-Principal et al., 2014; Sirianni et al., 2010;  
53 Sun, Luo, & Liu, 2014; Zhao et al., 2014) activities. In 2012, our group added the first  
54 description of hydroxytyrosol as an anti-angiogenic compound able to inhibit several key steps  
55 in the angiogenic process. In fact, we demonstrated that hydroxytyrosol (but not tyrosol)  
56 induced endothelial cell apoptosis and changes in cell cycle distribution as well as inhibiting  
57 endothelial cell proliferation, migration and differentiation into "capillary-like" tubes (Fortes et  
58 al., 2012). Furthermore, that work also identified matrix metalloproteinase 2 (MMP-2) as one of  
59 the molecular targets of the anti-angiogenic action caused by hydroxytyrosol. Since the  
60 publication of that article, additional data have been published regarding the roles of  
61 hydroxytyrosol as an anti-angiogenic compound. Several molecular targets have been identified  
62 contributing to the anti-angiogenic effects of hydroxytyrosol, including inhibition of MMP-9,

63 cyclooxygenase 2 and vascular endothelial growth factor receptor-2 (VEGFR-2)  
64 phosphorylation (Lamy, Ouanouki, Beliveau & Desrosiers, 2014; Scoditti et al., 2012; Scoditti  
65 et al., 2014). Furthermore, hydroxytyrosol has been recently shown to have protective effects  
66 against rheumatoid arthritis, an angiogenesis-dependent disease (Silva et al., 2015).

67 The identification of MMPs as molecular targets for hydroxytyrosol suggests that this  
68 compound can alter extracellular matrix remodeling (Fortes, García-Vilas, Quesada & Medina,  
69 2012; Scoditti et al., 2014), a key step in the angiogenic process. Therefore, the first aim of the  
70 present work was to study the effects of hydroxytyrosol on key extracellular matrix remodeling  
71 enzymes expressed in endothelial cells. On the other hand, in spite of the recent efforts to get  
72 deep insights on the anti-angiogenic potential of hydroxytyrosol there is still no data available  
73 demonstrating its potential inhibitory effects in *ex vivo* or *in vivo* models of angiogenesis. The  
74 second aim of this work was to test the anti-angiogenic potential of hydroxytyrosol in the *ex*  
75 *vivo* aortic ring and the *in vivo* CAM angiogenesis models.

76

## 77 **2. Materials and methods**

### 78 *2.1. Chemicals*

79 Supplements and other chemicals not listed in this section were obtained from Sigma  
80 Chemicals Co. (St. Louis MO, USA). Cell culture media, penicillin, streptomycin and  
81 amphotericin were purchased from Biowhittaker (Walkersville, MD, USA). Fetal bovine serum  
82 (FBS) and human serum (HS) were products of Harlan-Seralb (Belton, United Kingdom).  
83 Plastics for cell culture were supplied by NUNC (Rockilde, Denmark) and VWR (West Chester,  
84 Pennsylvania, USA). Hydroxytyrosol was supplied by Extrasynthèse (Lyon, France).

85

### 86 *2.2. Cell culture*

87 Most of the procedures described in Materials and methods have been previously used by  
88 our research group for other studies (see, for instance [Garcia-Vilas et al. 2013, Martínez-Poveda](#)

89 [et al. 2013](#)). Bovine aorta endothelial cells (BAEC) were isolated from bovine aortic arches, as  
90 previously described (Gospodarowicz & Moran, 1975), and maintained in Dulbecco's modified  
91 Eagle's medium (DMEM) containing glucose (1 g/L), glutamine (2 mM), penicillin (50  
92 IU/mL), streptomycin (50 mg/L), amphotericin (1.25 mg/L), 10% fetal bovine serum.

93

### 94 *2.3. RNA isolation and purification and cDNA synthesis*

95 Cells at 80% of confluence in 6-well plates were treated with or without 1mM of  
96 hydroxytyrosol for 24 h. After incubation, cells were harvested and washed (PBS). Total RNA  
97 was isolated with the GeneElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich)  
98 according to the purchaser's instructions.

99 cDNA synthesis was carried out with the iScript cDNA synthesis kit (BioRad).

100

### 101 *2.4. qPCR*

102 For quantitative RT-PCR (qPCR), total RNA isolation and complementary DNA synthesis  
103 were performed as described above and PCR reactions were done using KAPA SYBR Fast  
104 Master Mix (2x) Universal (KAPA Biosystems) in an Eco Real-Time PCR System. qPCR was  
105 performed in triplicate for each sample in keeping with the manufacturer's instructions. All  
106 qPCR data were normalized to GAPDH expression (Martínez-Poveda et al. 2013). Primers,  
107 amplicon size, and qPCR conditions for each gene are shown in Table 1.

108

### 109 *2.5. Animals and ethical statement*

110 All experimental procedures with animals were conducted in accordance with the Spanish  
111 Legislation (Real Decreto 53/2013, BOE, 34/-11421, 2013) in compliance with the European  
112 Community Directive 2010/63/EU regulating the use and care of laboratory animals. The

113 protocols were approved by the Ethics Committee for Animal Experiments of the University of  
114 Málaga.

115

#### 116 2.6. *Ex vivo rat aortic ring assay*

117 Thoracic aortas were removed from 12 week old rats and immediately transferred to a  
118 culture dish containing DMEM. The perioaortic fibroadipodise tissue was carefully removed  
119 with fine microdissecting forceps and iridectomy scissors paying special attention not to  
120 damage the aortic wall. Afterwards, 1-mm aortic rings were sectioned and embedded in a rat tail  
121 interstitial collagen gel (1.5 mg/mL) prepared by mixing 7.5 volumes of 2 mg/mL collagen, 1  
122 volume of 10x HBBS, 1.5 volumes of 186 mM NaHCO<sub>3</sub> and 0.1 volumes of 1 M NaOH to  
123 adjust the pH to 7.4. Collagen gels containing the aortic rings were polymerized in cylindrical  
124 agarose wells and kept in triplicate at 37°C in 60 mm diameter Petri dishes (bacteriological  
125 polysterene, Falcon, Becton Dickinson, Lincoln Park, New Jersey). Each Petri dish contained 6  
126 mL of MCDB131 medium supplemented with 1% L-glutamine, 25 mM NaHCO<sub>3</sub>, 100 U/mL  
127 penicillin, 100 µg/mL streptomycin, in presence of hydroxytyrosol or etanol (vehicle). Cultures  
128 were kept at 37°C, 5% CO<sub>2</sub> in a humidified environment, and photographs were taken after 6, 9  
129 and 14 days. The antiangiogenic response was quantified by microvessel counting according to  
130 published criteria (Nicosia & Ottinetti, 1990).

131

#### 132 2.7. *In vivo chorioallantoic membrane (CAM) assay*

133 Fertilized chick eggs were incubated horizontally at 38°C in a humidified incubator,  
134 windowed by day 3 of incubation and processed by day 8. The indicated amount of  
135 hydroxytyrosol was added to a 1% solution of methylcellulose in water, and 10 µL drops of this  
136 solution were allowed to dry on a Teflon-coated surface in a laminar flow hood. Then, the  
137 methylcellulose disks were implanted on the CAMs, and the eggs were sealed with adhesive  
138 tape and returned to the incubator for 48 h (Garcia-Vilas et al. 2013). Negative controls were

139 always made with ethanol (vehicle) mixed with methylcellulose. After the reincubation, CAMs  
140 were examined under a stereomicroscope. The assay was scored as positive when two  
141 independent observers reported a significant reduction of vessels in the treated area.

142

### 143 *2.8. Statistical analysis*

144 For all of the assays, at least three independent experiments were carried out. Results are  
145 expressed as means  $\pm$  SD. Statistical significance was determined by using Student's paired  
146 simple test. Values of  $p < 0.05$  were considered to be significant.

147

## 148 **3. Results**

149

### 150 *3.1. Hydroxytyrosol induces changes in the expression levels of genes involved in ECM* 151 *remodeling in endothelial cells*

152 To fulfil the first goal of our work, we analyzed by qPCR the effects of 1 mM  
153 hydroxytyrosol treatment of BAEC for 24 h on the expression levels of messenger  
154 corresponding to a number of genes involved in ECM remodeling. The primers, annealing  
155 temperature and amplicon sizes are summarized in Table 1. Table 2 summarizes the qPCR  
156 quantitative data for the 9 tested potential targets. Both MMP-1 and MMP-2 mRNA expression  
157 levels were drastically diminished by hydroxytyrosol, whereas three out of four tissue inhibitors  
158 of metalloproteinases (namely, TIMP-1, -2 and -4) mRNA expression levels were increased  
159 several fold. On the other hand, the mRNA levels for urokinase-type plasminogen activator  
160 (uPA), another ECM remodeling enzyme, were also drastically diminished upon hydroxytyrosol  
161 treatment, whereas the levels of the messenger for its specific receptor (uPAR) increased more  
162 than 20-fold. Finally, we could not detect any signal for plasminogen activator inhibitor 1 (PAI-  
163 1) mRNA.

164



165 3.2. *Hydroxytyrosol has a very potent inhibitory effect on the ex vivo rat aortic ring*  
166 *angiogenesis assay*

167 The second goal of this work was to test the anti-angiogenic potential of hydroxytyrosol in  
168 the *ex vivo* aortic ring and the *in vivo* CAM angiogenesis models. Figure 1 clearly shows that  
169 hydroxytyrosol was able to induce very strong inhibitory effects in the *ex vivo* aortic ring assay,  
170 even at concentrations much lower than those used previously by us to show its *in vitro* anti-  
171 angiogenic effects (Fortes, García-Vilas, Quesada & Medina, 2012). At 0.25 mM  
172 hydroxytyrosol the inhibition of microvessel outgrowth from the aortic rings was complete after  
173 6, 9 and 14 days of incubation. At 0.125 mM hydroxytyrosol we observed outgrowing of  
174 proliferative endothelial cells from the aortic ring but these cells were not forming microvessel  
175 tubes. Furthermore, there were partial inhibitory effects for 62.5  $\mu$ M hydroxytyrosol.

176

177 3.3. *Hydroxytyrosol inhibits in vivo angiogenesis*

178 Figure 2 shows that in untreated, control CAMs, blood vessels form a spatially-oriented and  
179 dense network of vascular structures with progressively smaller diameters as they branch.  
180 Hydroxytyrosol-treated CAMs showed inhibited angiogenesis, as revealed by an inhibition of  
181 new vessel formation within the area covered by the methylcellulose discs, a centrifugal growth  
182 of peripheral vessels, avoiding the treated area, and an overall decrease in vascular density.  
183 Table 3 summarizes the results obtained with the CAM assay. Positive, inhibitory effects were  
184 observed in 90% of eggs treated with 800 nmol of hydroxytyrosol. The inhibition was still  
185 observed in more than half of the CAMs treated with 400 nmol of hydroxytyrosol. For  
186 treatments with 200 and 100 nmol of hydroxytyrosol, 42% and 13% of the eggs scored positive.  
187 No inhibitory effect was observed in eggs treated with 50 nmol of hydroxytyrosol.

188

189 **4. Discussion**

190 As mentioned in the Introduction, a number of very different biological effects have been  
191 shown for hydroxytyrosol, underscoring its preventive and pharmacological potential. Our  
192 group demonstrated for the first time that hydroxytyrosol also behaves as an anti-angiogenic  
193 compound *in vitro* (Fortes, García-Vilas, Quesada & Medina, 2012). One of the molecular  
194 targets for this effect of hydroxytyrosol was the extracellular remodeling enzyme MMP-2, which  
195 plays a key role in the basal membrane destruction needed for the migration and invasion of  
196 proliferative endothelial cells during the angiogenic process (Stetler-Stevenson, 1999). This  
197 result was consistent with the description by another independent research group of the  
198 suppression of MMP-9 expression by hydroxytyrosol in both human endothelial cells (Scoditti,  
199 et al., 2012) and activated human monocytes (Scoditti, et al., 2014). Our qPCR results (Table 2)  
200 indicate that, indeed, hydroxytyrosol seems to have a global stimulating effect on ECM  
201 remodeling by both decreasing the expression levels of genes coding for extracellular matrix  
202 remodeling enzymes (MMP-1, MMP-2, uPA) and increasing the levels of some of their  
203 inhibitors (TIMP-1, -2, and -4).

204 A particularly important molecular target of hydroxytyrosol is VEGFR-2, since it plays a key  
205 role as a master regulator of the pro-angiogenic phenotype. In fact, it has been shown that  
206 hydroxytyrosol is a very potent inhibitor of the specific autophosphorylation sites (Tyr951,  
207 Tyr1059, Tyr1175, and Tyr1214) of VEGFR-2, thus inhibiting angiogenesis (Lamy, Ouanouki,  
208 Beliveau, & Desrosiers, 2014). These and other molecular data strongly suggested that  
209 hydroxytyrosol might have protective effects on angiogenesis-dependent diseases. This seems  
210 to be the case for age-related macular degeneration and rheumatoid arthritis (Granner, Maloney,  
211 Anteck, Correa & Burnier, 2013; Silva et al., 2015). Nonetheless, there is still need additional  
212 pre-clinical data showing modulatory effects of hydroxytyrosol beyond the *in vitro* situation to  
213 boost the interest to test the hydroxytyrosol potential for its clinical use. In this context, both *ex*  
214 *vivo* and *in vivo* assays seem required and useful. To our knowledge, the only available study  
215 showing an additional and indirect evidence of the anti-angiogenic effect of hydroxytyrosol *in*  
216 *vivo* was the article showing that hydroxytyrosol suppresses the growth of human hepatocellular

217 carcinoma through the inactivation of both AKT and NF- $\kappa$ B pathways (Zhao et al., 2014). In  
218 that article, figure 5C shows a histogram with the quantification of microvessel density in  
219 orthotopic hepatocellular carcinoma tumors stained for the microvessel marker CD31. In the  
220 present work, we have used two very popular pre-clinical angiogenesis assays, namely,  
221 the *ex vivo* aortic ring assay and the *in vivo* CAM assay. The *ex vivo* aortic ring assay  
222 allows for the analysis of cell proliferation, migration, tubule-like formation, microvessel  
223 branching and perivascular recruitment and remodeling (Baker et al., 2012). The CAM assay is  
224 the most frequently used *in vivo* assay of angiogenesis (Ribatti, 2008). The results obtained to  
225 fulfil the second aim of the present work have contributed to provide clear and remarkable  
226 evidence that, indeed, the anti-angiogenic effects of hydroxytyrosol observed previously *in vitro*  
227 are strongly confirmed by both *ex vivo* and *in vivo* angiogenesis assays carried out in the present  
228 work (Figures 1 and 2, and Table 3).

229 Interestingly, the effects described in the present work were obtained with hydroxytyrosol  
230 doses within the range described previously as absorbed from a sustained and moderate dose of  
231 virgin olive oil, similar to that corresponding to its daily intake in a typical Mediterranean diet  
232 (Miró-Casas et al., 2003).

233 The results presented in this work can be considered a step further toward translational  
234 studies to be carried out in the near future regarding the potential use of hydroxytyrosol in  
235 angioprevention and for the pharmacological inhibition of angiogenesis.

236

### 237 **Conflict of interest**

238 The authors declare that they have no financial or other conflict of interest.

239

### 240 **Acknowledgements**

241 This work was supported by grants BIO2014-56092-R (MINECO and FEDER) and P12-  
242 CTS-1507 (Andalusian Government and FEDER). The “CIBER de Enfermedades Raras” is an

243 initiative from the ISCIII (Spain). The funders had no role in the study design, data collection  
244 and analysis, decision to publish or preparation of the manuscript.  
245

246 **References**

- 247 Baker, M., Robinson, S. D., Lechertier, T., Barber, P. R., Tavora, B., D'Amico, G.,  
248 Jones, D. T., Vojnovic, B., & Hodivala-Dilke, K. (2012). Use of the mouse  
249 aortic ring assay to study angiogenesis. *Nature Protocols*, 7(1), 89-104.
- 250 Commission Regulation (EU) 432/2012 of 16 May 2012 establishing a list of permitted  
251 health claims made on foods, other than those referring to the reduction of  
252 disease risk and to children's development and health. O.J. 2012, L136/1.  
253 (2012).
- 254 De La Cruz, J. P., Ruiz-Moreno, M. I., Guerrero, A., Reyes, J. J., Benitez-Guerrero, A.,  
255 Espartero, J. L., & Gonzalez-Correa, J. A. (2015). Differences in the  
256 Neuroprotective Effect of Orally Administered Virgin Olive Oil (*Olea*  
257 *europaea*) Polyphenols Tyrosol and Hydroxytyrosol in Rats. *Journal of*  
258 *Agricultural and Food Chemistry*, 63(25), 5957-5963.
- 259 Fortes, C., García-Vilas, J. A., Quesada, A. R., & Medina, M. A. (2012). Evaluation of  
260 the anti-angiogenic potential of hydroxytyrosol and tyrosol, two bio-active  
261 phenolic compounds of extra virgin olive oil, in endothelial cell cultures. *Food*  
262 *Chemistry*, 134, 134-140.
- 263 Fuccelli, R., Fabiani, R., Sepporta, M. V., & Rosignoli, P. (2015). The hydroxytyrosol-  
264 dependent increase of TNF-alpha in LPS-activated human monocytes is  
265 mediated by PGE2 and adenylate cyclase activation. *Toxicology In Vitro*, 29(5),  
266 933-937.
- 267 Gallardo, E., Madrona, A., Palma-Valdes, R., Espartero, J. L., & Santiago, M. (2015).  
268 Effect of intracerebral hydroxytyrosol and its nitroderivatives on striatal  
269 dopamine metabolism: A study by in vivo microdialysis. *Life Sciences*, 134, 30-  
270 35.
- 271 García-Vilas, J.A., Quesada, A.R., & Medina, M.A. (2013) 4-Methylumbelliferone  
272 inhibits angiogenesis in vitro and in vivo. *Journal of Agricultural and Food*  
273 *Chemistry*, 61, 4063-4071.
- 274 Gospodarowicz, D., & Moran, J. S. (1975). Mitogenic effect of fibroblast growth factor  
275 on early passage cultures of human and murine fibroblasts. *The Journal of Cell*  
276 *Biology*, 66(2), 451-457.
- 277 Granados-Principal, S., El-Azem, N., Pamplona, R., Ramirez-Tortosa, C., Pulido-  
278 Moran, M., Vera-Ramirez, L., Quiles, J. L., Sanchez-Rovira, P., Naudi, A.,  
279 Portero-Otin, M., Perez-Lopez, P., & Ramirez-Tortosa, M. (2014).  
280 Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in  
281 doxorubicin-induced cardiotoxicity in rats with breast cancer. *Biochemical*  
282 *Pharmacology*, 90(1), 25-33.
- 283 Granner, T., Maloney, S., Anteck, E., Correa, J. A., & Burnier, M. N., Jr. (2013). 3,4  
284 dihydroxyphenyl ethanol reduces secretion of angiogenin in human retinal  
285 pigment epithelial cells. *British Journal of Ophthalmology*, 97(3), 371-374.
- 286 Lamy, S., Ouanouki, A., Beliveau, R., & Desrosiers, R. R. (2014). Olive oil compounds  
287 inhibit vascular endothelial growth factor receptor-2 phosphorylation.  
288 *Experimental Cell Research*, 322(1), 89-98.
- 289 Lopez de Las Hazas, M. C., Rubio, L., Kotronoulas, A., de la Torre, R., Sola, R., &  
290 Motilva, M. J. (2015). Dose effect on the uptake and accumulation of  
291 hydroxytyrosol and its metabolites in target tissues in rats. *Molecular Nutrition*  
292 *& Food Research*, 59(7), 1395-1399.
- 293 Martínez-Poveda, B., García-Vilas, J.A., Cárdenas, C., Melgarejo, E., Quesada, A.R., &  
294 Medina, M.A. (2013). The brominated compound aerophysinin-1 inhibits

- 295 proliferation and the expression of key pro-inflammatory molecules in human  
296 endothelial and monocyte cells. *Plos One*, 8(1), e55203.
- 297 Miró-Casas, E., Covas, M.I., Fitó, M., Farré-Albadalejo, M., Marrugat, J., & De la  
298 Torre, R. (2003). Tyrosol and hydroxytyrosol are absorbed from moderate and  
299 sustained doses of virgin olive oil in humans. *European Journal of Clinical  
300 Nutrition*, 57, 186-190.
- 301 Mnafigui, K., Hajji, R., Derbali, F., Khlif, I., Kraiem, F., Ellefi, H., Elfeki, A., Allouche,  
302 N., & Gharsallah, N. (2015). Protective Effect of Hydroxytyrosol Against  
303 Cardiac Remodeling After Isoproterenol-Induced Myocardial Infarction in Rat.  
304 *Cardiovascular Toxicology*.
- 305 Nicosia, R. F., & Ottinetti, A. (1990). Growth of microvessels in serum-free matrix  
306 culture of rat aorta. A quantitative assay of angiogenesis *in vitro*. *Laboratory  
307 Investigation*, 63(1), 115-122.
- 308 Owen, R. W., Giacosa, A., Hull, W. E., Haubner, R., Wurtele, G., Spiegelhalder, B., &  
309 Bartsch, H. (2000). Olive-oil consumption and health: the possible role of  
310 antioxidants. *The Lancet Oncology*, 1, 107-112.
- 311 Persia, F. A., Mariani, M. L., Fogal, T. H., & Penissi, A. B. (2014). Hydroxytyrosol and  
312 oleuropein of olive oil inhibit mast cell degranulation induced by immune and  
313 non-immune pathways. *Phytomedicine*, 21(11), 1400-1405.
- 314 Ribatti, D. (2008). Chick embryo chorioallantoic membrane as a useful tool to study  
315 angiogenesis. *International Review of Cell Molecular Biology*, 270, 181-224.
- 316 Samuel, S. M., Thirunavukkarasu, M., Penumathsa, S. V., Paul, D., & Maulik, N.  
317 (2008). Akt/FOXO3a/SIRT1-mediated cardioprotection by n-tyrosol against  
318 ischemic stress in rat *in vivo* model of myocardial infarction: switching gears  
319 toward survival and longevity. *The Journal of Agricultural and Food Chemistry*,  
320 56(20), 9692-9698.
- 321 Scoditti, E., Calabriso, N., Massaro, M., Pellegrino, M., Storelli, C., Martines, G., De  
322 Caterina, R., & Carluccio, M. A. (2012). Mediterranean diet polyphenols reduce  
323 inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human  
324 vascular endothelial cells: a potentially protective mechanism in atherosclerotic  
325 vascular disease and cancer. *Archives of Biochemical Biophysics*, 527(2), 81-89.
- 326 Scoditti, E., Nestola, A., Massaro, M., Calabriso, N., Storelli, C., De Caterina, R., &  
327 Carluccio, M. A. (2014). Hydroxytyrosol suppresses MMP-9 and COX-2  
328 activity and expression in activated human monocytes via PKC $\alpha$  and  
329 PKC $\beta$ 1 inhibition. *Atherosclerosis*, 232(1), 17-24.
- 330 Silva, S., Sepodes, B., Rocha, J., Direito, R., Fernandes, A., Brites, D., Freitas, M.,  
331 Fernandes, E., Bronze, M. R., & Figueira, M. E. (2015). Protective effects of  
332 hydroxytyrosol-supplemented refined olive oil in animal models of acute  
333 inflammation and rheumatoid arthritis. *The Journal of Nutritional Biochemistry*,  
334 26(4), 360-368.
- 335 Sirianni, R., Chimento, A., De Luca, A., Casaburi, I., Rizza, P., Onofrio, A., Iacopetta,  
336 D., Puoci, F., Ando, S., Maggiolini, M., & Pezzi, V. (2010). Oleuropein and  
337 hydroxytyrosol inhibit MCF-7 breast cancer cell proliferation interfering with  
338 ERK1/2 activation. *Molecular Nutrition & Food Research*, 54(6), 833-840.
- 339 Stetler-Stevenson, W. G. (1999). Matrix metalloproteinases in angiogenesis: a moving  
340 target for therapeutic intervention. *The Journal of Clinical Investigation*, 103(9),  
341 1237-1241.
- 342 Sun, L., Luo, C., & Liu, J. (2014). Hydroxytyrosol induces apoptosis in human colon  
343 cancer cells through ROS generation. *Food & Function*, 5(8), 1909-1914.

- 344 Tutino, V., Orlando, A., Russo, F., & Notarnicola, M. (2015). Hydroxytyrosol Inhibits  
345 Cannabinoid CB1 Receptor Gene Expression in 3T3-L1 Preadipocyte Cell Line.  
346 *The Journal of Cellular Physiology*.
- 347 Zhao, B., Ma, Y., Xu, Z., Wang, J., Wang, F., Wang, D., Pan, S., Wu, Y., Pan, H., Xu,  
348 D., Liu, L., & Jiang, H. (2014). Hydroxytyrosol, a natural molecule from olive  
349 oil, suppresses the growth of human hepatocellular carcinoma cells via  
350 inactivating AKT and nuclear factor-kappa B pathways. *Cancer Letters*, 347(1),  
351 79-87.
- 352 Zheng, A., Li, H., Xu, J., Cao, K., Li, H., Pu, W., Yang, Z., Peng, Y., Long, J., Liu, J.,  
353 & Feng, Z. (2015). Hydroxytyrosol improves mitochondrial function and  
354 reduces oxidative stress in the brain of db/db mice: role of AMP-activated  
355 protein kinase activation. *British Journal of Nutrition*, 113(11), 1667-1676.
- 356 Zoric, N., Horvat, I., Kopjar, N., Vucemilovic, A., Kremer, D., Tomic, S., & Kosalec, I.  
357 (2013). Hydroxytyrosol expresses antifungal activity *in vitro*. *Current Drug*  
358 *Targets*, 14(9), 992-998.  
359
- 360

361 **Table 1.** Primers used for qPCR with indication of their respective annealing temperatures  
 362 and amplicon sizes.  
 363

Gene	Primers	Annealing temperature (°C)	Amplicon size (bp)
MMP-1	Forward: gacttagtccagaatacctg Reverse: caaagaattcctgcatttgc	60	121
MMP-2	Forward: gacatacatctttgctggagac Reverse: acgctcttcagacttgggtct	60	200
TIMP-1	Forward: gggacaccagaagtcaacca Reverse: ggcttggaaacctttatacatc	63	81
TIMP-2	Forward: aagcggtcagtgagaaggaa Reverse: ttcaggccctttgaacatc	65	112
TIMP-3	Forward: gcagcggaccacaacagcta Reverse: ccggatcacgatgtcggagt	68	150
TIMP-4	Forward: agggagagcctgaatcatca Reverse: gactgcatagcaagtgtg	65	68
uPA	Forward: cgccacacactgcttcag Reverse: ccccttgcgtgttggagtt	60	310
uPAR	Forward: gcccaatcctggagcttga Reverse: tcccttgcagctgtaacact	60	63
PAI-1	Forward: gcacaacccccacaggaaca Reverse: gtcccgatgaaggcgtcttt	65	81



364 **Table 2.** Relative expression values of mRNAs for some extracellular matrix remodelling  
 365 enzymes and their inhibitors in BAEC treated with hydroxytyrosol.

	<b>MMP-1</b>	<b>MMP-2</b>	<b>TIMP-1</b>	<b>TIMP-2</b>	<b>TIMP-3</b>	<b>TIMP-4</b>	<b>uPA</b>	<b>uPAR</b>	<b>PAI-1</b>
<b>BAEC</b>	16.9 ± 0.5	0.28 ± 0.2	3857.3 ± 537.1	418.0 ± 123.9	14.76 ± 1.47	377.6 ± 209.6	20.95 ± 12.1	2195.8 ± 433.0	-

366 qPCR was carried out as described in Materials and Methods. All qPCR data were  
 367 normalized with GAPDH expression levels. Data are given as means ± S.D. and they are  
 368 percentages of expression taking the corresponding expression values in control, untreated cells  
 369 as 100%.

370

371

372

373 **Table 3.** Inhibition of *in vivo* angiogenesis by hydroxytyrosol (HT) as determined by the  
374 CAM assay.

HT (nmol/CAM)	Positive/Total	Inhibition (%)
0	0/8	0
50	0/6	0
100	1/8	13
200	5/12	42
400	5/8	63
600	5/7	71
800	9/10	90

375

376

377 **Figure legends**

378

379 **Fig. 1.** Hydroxytyrosol inhibits microvessel outgrowth in the *ex vivo* rat aortic ring assay.

380 (A) Representative samples of the aortic ring without or with treatment. (B) Quantification of  
381 the area occupied by new microvessels in controls, controls treated with VEGF and rings treated  
382 with 31.2  $\mu$ M or 62.5  $\mu$ M hydroxytyrosol and VEGF. The results are the mean  $\pm$  SD of three  
383 different assays.

384

385 **Fig. 2.** Hydroxytyrosol inhibits angiogenesis *in vivo* in the CAM assay. Arrows point rebound  
386 of vessels outward from the treated area. Asterisks indicate disrupted vessels.

387

388

389


390

391


392

Figure 1

[Click here to download high resolution image](#)




**B)**



---

Control

---



HT (800 nmol)

---

